1. USD

    327.58

    Today's change

    0.70 / +0.21%

    1 year change

    +32.98%

    As of Sep 17 2014 21:00 BST. Data delayed by at least 15 minutes.

Search for Biogen Idec Inc and
  1. July 31, 2014

    Stocks: the value is out there

    The problem, we are assured, is localised. Yes, reliable measures of valuation for stocks – as a group – are elevated. The...

  2. June 30, 2014

    AbbVie puts investor patience in European drugmakers to the test

    Will the last mid-sized European drugmaker please turn off the lights? AbbVie’s £27bn takeover approach for UK-listed Shire...

  1. April 1, 2014

    Bristol-Myers Squibb: side effects

    One of these things is not like the others, as Big Bird sings. Look at the mega-cap pharma and biotech stocks. In the near...

  2. March 27, 2014

    Baxter: own devices

    Once you’ve played the trump card, what do you do with the rest of your hand? That’s a question Baxter International’s...

  3. March 25, 2014

    Investors brace for end of the biotech run

    When the long bull run in biotech stocks came to a shuddering halt last week, Wall Street looked south to Capitol Hill for...

  4. July 5, 2013

    Financials buoy US stock markets

    The S&P 500 finished the week with a rally after Treasury rates rose sharply following the release of strong US jobs data,...

  5. June 14, 2013

    Elan opens formal sale process

    Elan, the Irish pharmaceutical business facing a $6.7bn hostile bid from Royalty Pharma, said on Friday it was putting...

  6. June 13, 2013

    Royalty suffers setback in Elan poll

    Royalty Pharma’s hostile $6.7bn takeover for Dublin-based Elan received a sharp setback on Thursday as the US group’s...

  7. June 7, 2013

    Royalty Pharma raises Elan offer

    The bitter battle for Elan intensified on Friday after private equity group Royalty Pharma raised its all-cash offer for the...

  8. May 31, 2013

    Elan / Royalty Pharma: number crunchers

    Every takeover should be finally decided on the basis of valuation. So the battle between Royalty Pharma and Elan Corp could...

  9. May 13, 2013

    Elan seeks to weaken hostile bid with $1bn Theravance deal

    Elan, the Irish drug company facing a hostile bid from Royalty Pharma, plans to pay $1bn to buy the rights for four...

  10. April 15, 2013

    Royalty Pharma raises offer for Elan

    Royalty Pharma has increased its offer for Elan , the Irish pharmaceutical business, to up to $12 a share with the launch of...

  11. April 3, 2013

    Irish regulator sets Elan bid deadline

    The Irish takeover regulator has stepped into the battle for control of Dublin-based pharmaceutical group Elan by setting a...

  12. March 6, 2013

    Royalty Pharma steps up battle for Elan

    Royalty Pharma stepped up its $6.6bn battle for Elan by questioning the experience of the Irish pharmaceutical group’s...

  13. March 4, 2013

    Elan pledges royalties-linked dividend

    Elan, the Irish-based drug company, has moved to counter a $6.6bn takeover bid by pledging to pay a fifth of the royalties...

  14. February 25, 2013

    Elan / Royalty Pharma: gone shopping

    Turning a company into a cash shell means one of two things. Either it is about to go shopping, or it appears on someone’s...

  15. February 23, 2013

    Elan unveils share $1bn buyback

    Elan, the Irish-based drug company, has pledged to buy back $1bn of its own shares, refinance debt and seek fresh...

  16. February 6, 2013

    Biogen to buy Elan’s stake in MS drug

    Biogen Idec, the US biotechnology company, said on Wednesday that it would pay $3.25bn in cash to acquire Elan Corp’s stake...

  17. February 6, 2013

    Elan / Biogen: where are the drugs?

    Elan Corp has become the drug company that has no drugs. The Dublin-based biotechnology group has been looking for a...

  18. July 15, 2012

    US biotech warning over Europe price cuts

    European price cuts threaten the development of future medicines by squeezing drug companies’ research budgets, the head of...

  19. May 6, 2012

    Drugmakers see $33bn bout of M&A activity

    A recent spate of takeovers in healthcare, as drugmakers seek to replace expiring drug patents, has made it the busiest...

  20. January 30, 2012

    US pharma: keep taking the tablets

    Time to get off the drugs? We’ve had a good time, after all. Over the past 12 months, the average return of the...

  21. November 7, 2011

    Biogen Idec: waking from the dream

    The stock investors’ dream is a company whose risks are diminishing while its return potential is growing. Biogen Idec has...

  22. August 10, 2011

    Study reveals genetic variations behind MS

    A huge international study of multiple sclerosis has revealed 57 genetic variations that underlie the disease. The results...

  23. April 11, 2011

    Wall St energy shares hit by growth report

    News that Endo Pharmaceuticals was acquiring American Medical Systems helped lift the healthcare sector, but the wider...

  24. March 11, 2011

    Icahn warns another downturn may lie ahead

    Carl Icahn has joined the growing chorus of prominent investors warning that another downturn may lie ahead. “You’ve got to...

  25. October 27, 2010

    Elan cuts losses by boosting sales

    Falling research costs and rising sales of its headline multiple sclerosis drug helped Elan, the Irish pharmaceutical group,...

  26. July 26, 2010

    Wall Street rally continues as all sectors post gains

    US stocks were lifted on Monday by better housing data than expected and a forecast earnings rise by FedEx, the delivery...

  27. July 16, 2010

    Elan pays $204m epilepsy drug fine

    Elan has agreed to pay a $204m (£133m) fine over its marketing practices for its anti-epilepsy drug Zonegran, in a...

  28. July 2, 2010

    Weak payroll figures keep S&P in negative territory

    US stocks closed lower for the second consecutive week on Friday with a number of disappointing economic reports weighing on...

  29. June 11, 2010

    The last word: Why researchers are no longer moving from the lab to the boardroom

    Wanted: chief executive for pharmaceutical company to bring lucrative new medicines to market. Scientists need not apply....

  30. June 10, 2010

    Researchers are out of race for the top job

    Wanted: chief executive for pharmaceutical company to bring lucrative new medicines to market. Scientists need not apply....

  31. March 8, 2010

    AstraZeneca job cuts reflect new landscape

    When AstraZeneca revealed details last week of 3,500 job cuts across its global research and development operations, it was...

  32. December 3, 2009

    MS drugs scheme fails to deliver results

    A pioneering scheme designed by the government to impose a money-back guarantee on pharmaceutical companies if their drugs...

  33. October 25, 2009

    J&J wants deals with rivals to share risk

    Johnson & Johnson, the US healthcare group, will in future take more long-term minority stakes and forge alliances with...

  34. October 24, 2009

    Elan hit by Tysabri questions

    Irish drugs group Elan plunged 20.5 per cent to €3.42 yesterday, as European markets headed lower. European regulators...

  35. October 23, 2009

    Elan hit by Tysabri questions

    Irish drugs group Elan plunged 20.5 per cent to €3.42 on Friday, as European markets headed lower. European regulators...

  36. September 30, 2009

    Pharmaceuticals: Same end, entirely different means

    Their headquarters stand less than two kilometres apart, on opposite sides of the river Rhine in the city of Basel in...

  37. September 15, 2009

    Elan revises J&J deal to appease Biogen

    Elan, the Irish domiciled biotech company, will receive $115m less than previously agreed from Johnson & Johnson as part of...

  38. September 15, 2009

    Elan revises J&J deal to appease Biogen

    Elan, the Irish domiciled biotech company, will receive $115m less than previously agreed from Johnson & Johnson as part of...

Search for Biogen Idec Inc and